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Previous studies have shown that influenza is associated with a substantial healthcare bur-
den in the United Kingdom (UK), but more studies are needed to evaluate the resource use
and direct medical costs of influenza in primary care and secondary care.
Methods
A retrospective observational database study in the UK to describe the primary care and
directly-associated secondary care resource use, and direct medical costs of acute respira-
tory illness (ARI), according to age, and risk status (NCT Number: 01521416). Patients with
influenza, ARI or influenza-related respiratory infections during 9 consecutive pre-pandemic
influenza peak seasons were identified by READ codes in the linked Clinical Practice
Research Datalink (CPRD) and Hospital Episodes Statistics (HES) dataset. The study
period was from 21st January 2001 to 31st March 2009.
Results
A total of 156,193 patients had�1 general practitioner (GP) episode of ARI, and a total of
82,204 patients received�1 GP prescription, at a mean of 2.5 (standard deviation [SD]: 3.0)
prescriptions per patient. The total cost of GP consultations and prescriptions equated to
£462,827 per year per 100,000 patients. The yearly cost of prescribed medication for ARI
was £319,732, at an estimated cost of £11,596,350 per year extrapolated to the UK, with
40% attributable to antibiotics. The mean cost of hospital admissions equated to a yearly
cost of £981,808 per 100,000 patients. The total mean direct medical cost of ARI over 9
influenza seasons was £21,343,445 (SD: £10,441,364), at £136.65 (SD: £66.85) per case.
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Conclusions
Extrapolating to the UK population, for pre-pandemic influenza seasons from 2001 to 2009,
the direct medical cost of ARI equated to £86 million each year. More studies are needed to
assess the costs of influenza disease to help guide public health decision-making for sea-
sonal influenza in the UK.
Introduction
The resource use and costs of seasonal influenza epidemics remains substantial despite many
countries recommending annual vaccination for either specific population groups that are vul-
nerable to infection (such as children, elderly adults, and anyone with chronic conditions), or
universal vaccination such as in the United States (US), Canada, and Australia.[1–4] However,
measuring the value of influenza vaccination is challenging because the clinical and economic
effect depends on the epidemic intensity of the influenza season, and the degree of vaccine
match with circulating viruses.
National influenza vaccination policies are generally guided by studies that have evaluated
influenza costs or the cost-effectiveness of influenza vaccination in different settings and
patient groups; in a review of 140 studies published up to 2012, the per capita cost of a case of
influenza illness ranged from $30 to $64, and 22 studies reported that influenza vaccination
was cost-saving.[5] In the United Kingdom (UK) publically-funded influenza vaccination is
recommended for people aged�65 years, pregnant women, carers and health and social care
workers, and anyone at increased risk of influenza infection or complications such as people
with asthma, diabetes, cardiovascular disease, or kidney disease.[4] The paediatric recommen-
dation for publically-funded vaccination in the UK is currently all children aged from 2 to 7
years/school year 3, and children aged�6 months if they have chronic health conditions.[4]
The publically-funded vaccination policy in the UK is supported by various analyses that
have assessed the burden of influenza illness and costs in the UK.[6–12] This includes a study
representing about 52.6 million people over 14 influenza seasons (1995–2009) in England and
Wales, which showed that vaccinating people aged�65 years and people at high-risk of influ-
enza disease was likely to be cost-effective (incremental cost-effectiveness ratio [ICER]: £7,475/
QALY).[8] The analysis also showed that vaccinating low-risk groups would also likely to be
cost-effective, with the highest net benefit achieved by including all children in the vaccination
programme.[8]
To help guide public health decision-making, more studies are needed that assess the bur-
den and cost of influenza disease in the UK including episodes of influenza in primary care
and secondary care, and an evaluation of risk factors associated with influenza episodes. To
address this, we conducted a retrospective, cross-sectional, observational study to evaluate the
primary care and directly-associated secondary care resource use, and direct medical costs of
acute respiratory illness (ARI) in patients with READ codes for acute respiratory illnesses in
the linked Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES)
dataset during influenza seasons between 2001 and 2009. Data from the CPRD/HES dataset,
the Health Protection Agency (HPA), and the Office of National Statistics (ONS), were used to
identify patients with�1 general practitioner episode of ARI (i.e. primary care) and patients
with linked secondary care data. The first analysis from the study provided data on vaccination
uptake and direct medical costs by vaccination status and degree of vaccine mismatch.[13]
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Here we report the resource use and direct medical costs of GP episodes of ARI and hospital
admissions in the total population, and according to age and risk status.
Methods
Design
This retrospective, cross-sectional, observational study was conducted to evaluate the resource
use and direct medical costs of GP episodes of ARI and linked hospital admissions during
influenza seasons in the study period of 21st January 2001 and 31st March 2009 in the UK
(NCT Number: 01521416). Approval for this study was obtained from the CPRD Independent
Scientific Advisory Committee (11_065) negating the need for individual patient consent. The
full methods are provided in S1 Data and are published elsewhere.[13]
Case definitions and data extraction
Fully anonymised data on patients who had�1 GP episode with a READ code identifying
influenza like illnesses (ARI) were extracted from the linked Clinical Practice Research Data-
link (CPRD)/Health Episode Statistics (HES) dataset for the study. Cases of ARI were identi-
fied using a broad range of READ codes describing influenza, influenza-like illness, or acute
upper or lower respiratory tract infection with influenza. For each influenza peak season, ARI
episodes recorded in the CPRD were identified.
For patients with linked data, the HES record was assessed for hospital admissions for influ-
enza or a complication following influenza, including data for 14 days before and after the
index ARI episode. Hospitalised patients were assessed for 28 days post-discharge.
Patients were categorised as low- or high-risk for influenza infection and related complica-
tions using criteria from the National Institute for Health and Care Excellence (NICE) and the
UK Department of Health.[4, 14]
READ codes for ARI in the CPRD and READ codes for high-risk conditions are shown in
S1 Data; Appendices 1 and 3 in S1 Data.
Influenza peak seasons analysed
The study was conducted from 2001 to 2009 covering 9 influenza seasons, up to the outbreak
of pandemic A(H1N1)pdm09 in the UK on the 27th of April 2009. GP episodes with any rele-
vant READ code recorded during periods of influenza peak season each year were included in
the study. The start and end of influenza peak season in each year was based on laboratory-
confirmed reports of respiratory pathogens circulating in the UK from the Health Protection
Agency (HPA) for the period November 2002 to December 2008.[15] Peak influenza season
was based on the weeks during which there was high viral circulation and ARI clinical events
based on HPA laboratory reports for influenza A and B and other respiratory infections.
Outcome measures
Burden of ARI. The outcome measures were the incidence of: ARI GP episodes, linked
hospital admissions, death, complications, and high-risk conditions: respiratory, central ner-
vous system, diabetes, chronic heart disease, pregnant, liver disease, renal disease, and immu-
nocompromised. The outcomes were assessed in the total population including all patients
with�1 ARI GP episode and the hospitalized population including patients with an index ARI
episode and a subsequent hospital admission. Subgroup analyses were performed by age (<5
years; 5–18 years; 19–49 years; 50–65 years,�65 years), complication status (complicated
cases and uncomplicated cases), and clinical risk group (low-risk and high-risk). Mortality was
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classified as being without hospital admission, in hospital, or within 28 days of discharge from
hospital.
Resource use and costs. GP consultations for ARI were classified as resource use in ‘pri-
mary care’. Prescriptions for medications from GPs were also classified as resource use in ‘pri-
mary care’. Medications were assessed by drug category: antipyretics/analgesics, antibiotics,
amantadine, aminoglycosides, nasal decongestants, antisecretory drugs and mucosal protec-
tants, and antihistamines. Antibiotics were assessed by class. Resource use was classified as
hospitalization if it was associated with patients who were admitted to hospital or who
attended a hospital out-patient appointment. Hospital resource use outcomes were: the inci-
dence of hospital admission, mean number of unique admissions, mean length of stay per hos-
pitalization, mean number of out-patient appointments, and route of hospital admission
(A&E, GP referral, or other). Medications prescribed in hospital were not captured. The inci-
dence of GP referrals to ambulatory out-patient appointments was also assessed.
The study was based on National Health Service (NHS) records from primary and second-
ary care providers in the UK. The cost perspective was that of the NHS and included all pri-
mary care and hospital admissions for ARI. GP consultation costs and out-patient visit costs
were from the Personal Social Services Research Unit (PSSRU) database:[16] GP consultation
£36, out-patient care £147, and hospital admission £686. Unit costs for hospitalizations were
derived from the NHS secondary care tariff for healthcare-related groups (HRG). All HRG
codes for a complication relevant to the study were grouped together to calculate a mean unit
cost for that complication. The analysis was based on 2011 costs expressed in £ (pounds
sterling).
Data analysis
No comparisons were made between study groups so there was no target sample size. All eligi-
ble patients within the database were used in the analysis. Raw data were cleaned before analy-
sis. It was assumed that a patient could experience only one ARI GP episode and one
hospitalization on one day. Data were extracted using MySQL, and analyses were conducted
in Microsoft Access, Microsoft Excel and Statistical Package for the Social Sciences (SPSS).
The burden of ARI, resource use, and costs were analysed descriptively in the total popula-
tion and by age, complication status, and risk status. The burden and resource use data were
reported as the number of patients and as a percentage of the total population. The data were
also provided as the incidence of the outcome per 100,000 population in the CPRD. The data
was extrapolated to the UK population using ONS; population estimates by year, and by age
group are publicly available and provided end of year estimates of the resident population
from 2001 to 2009:[17] Calculated from the CPRD/HES data extract, the yearly average num-
ber of patients in the CPRD/HES database in 2000–2009 was 1,662,953, and the average UK
population in 2001–2009 was 60,313,633, giving a multiplying factor of 36.3 which was used to
extrapolate the study data since the CPRD database was shown to be broadly representative of
the UK population [18]. The burden, resource use, and costs were assessed over the study
period (9 seasons) and for each season. Summary statistics were provided as mean values and




A total of 156,193 patients had�1 GP episode of ARI during the study period (total popula-
tion), with 82,204 patients receiving�1 GP prescription, at a mean of 2.5 (SD: 3.0)
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prescriptions per patient. The total cost of GP consultations and prescriptions during the
study period was £6,506,137, equating to a yearly cost of £462,827 per 100,000 patients. The
yearly cost of GP episodes of ARI ranged from £660,420 in 2007/08 to £904,644 in 2003/04. A
summary of primary care resource use and costs by age group is shown in Table 1. The total
yearly costs extrapolated to the UK population are shown in Fig 1. A summary of ambulatory
care resource use and costs is shown in S2 Data.
The total yearly cost of prescribed medications in the study was £319,732, and extrapolated
to the UK was estimated to be £104,367,150 (£11,596,350 per year), with 40% of this cost
Table 1. Primary care resource use and direct medical costs of acute respiratory illness by age and complication status in the CPRD population during influenza
seasons from 2001 to 2009.
Patients with �1 GP
episode, n








Total 156,193 178,304 82,204 2.5 (3.0) £6,506,137
<5 years 2,845 3,294 1,251 1.6 (1.0) £122,974
5–18
years
17,241 19,091 7,014 1.5 (1.0) £702,780
19–49
years
78,906 88,404 34,994 1.7 (1.7) £2,906,477
50–64
years
33,547 38,704 20,683 2.8 (3.0) £1,416,237
�65 years 23,654 28,811 18,262 4.3 (4.3) £1,067,038
CPRD, Clinical Practice Research Datalink; SD, standard deviation; GP, general practitioner.
https://doi.org/10.1371/journal.pone.0236472.t001
Fig 1. Resource use for acute respiratory illness in the CPRD/HES by influenza season extrapolated to the UK population
for corresponding years.
https://doi.org/10.1371/journal.pone.0236472.g001
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attributable to antibiotics (Fig 2). In the total population, the most commonly prescribed drug
categories were antibiotics (41.0%), analgesics (31.1%), and anti-secretory drugs and mucosal
protectants (11.6%) (Fig 2). Penicillin was the most commonly prescribed antibiotic
(n = 30,979; 21.2%). Among the 82,204 patients who received a GP prescription, 25.5% were
aged<5 years, 21.8% aged 5–18 years, 30.9% aged 19–49 years, 37.8% aged 50–64 years, and
38.5% aged�65 years (Fig 3).
Fig 2. Prescriptions by medication class (A) and antibiotic and antiviral use (B) for acute respiratory illness in the CPRD by influenza
season extrapolated to the UK population for corresponding years.CPRD, Clinical Practice Research Datalink.
https://doi.org/10.1371/journal.pone.0236472.g002
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Secondary care
A total of 1,601 (1.0%) patients were admitted to hospital, with a total of 1,856 hospital admis-
sions. In the total population, the total cost of hospital admissions was £13,801,634, equating
to a yearly cost of £981,808 per 100,000 patients. A summary of secondary care resource use
and direct medical costs is shown in Table 2.
A total of 908 (56.7%) patients were admitted via A&E, 532 (33.2%) patients via a GP refer-
ral, and 161 (10.1%) patients via another route. The mean length of hospital stay in the total
population was 11.3 (SD: 15.3) days, and the median length of hospital stay was 12.6 days. The
cost of secondary care in those admitted via A&E was £9,433 (SD: £3,584) per patient, and in
those admitted by GP referral was £8,150 (SD: £3,830) per patient. The average length of stay
by year was lowest in 2002/03 (10.0 days) and highest in 2008/09 (12.9 days). The yearly cost of
hospital admissions for ARI extrapolated to the UK population was £44,508,313 in 2002/03
and £85,803,090 in 2008/09 (Table 3).
Total direct medical costs
The total mean direct medical cost in the total population was £21,343,445 (SD:
£10,441,364), at a mean cost of £136.65 (SD: £66.85) per case (Table 4). By age subgroup,
the cost per case was £92.78 (<5 years), £57.19 (5–18 years), £61.21 (19–49 years), £116.32
(50–64 years), £477.72 (�65 years). Extrapolated to the UK population, the total estimated
cost of ARI in the study period was £774.1 million (SD: £378.7 million) or £86,011,699 per
year.
The highest total costs were incurred in high risk patients with CHD at £4,591,080 (SD:
£2,603,295), and the highest cost per case was in patients with renal disease at £13,773 (SD:
£6,656.23) per case (Table 5). Extrapolated to the UK population, the total cost in the study
period of patients with ARI and CHD was £166,513,855 (SD: £94,418,892), at a cost per case of
£18,750 (SD: £10,632) (Table 6).
Fig 3. Number of prescriptions for acute respiratory illness in the CPRD by age group in influenza seasons from 2001 to 2009.
CPRD, Clinical Practice Research Datalink.
https://doi.org/10.1371/journal.pone.0236472.g003
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Discussion
This retrospective, cross-sectional study over 9 influenza seasons between 2001 and 2009, iden-
tified 156,193 patients with�1 GP episode of ARI in the CPRD, of which 1,601 (1.0%) patients
were subsequently admitted to hospital. The cost of GP consultations and prescriptions was
£462,827 per 100,000 patients per year and the cost of hospital admissions was £981,808 per
100,000 patients per year. The total cost of prescribed medications extrapolated to the UK was
estimated at £11,596,350 per year, with £4.6m (40%) attributable to antibiotics, and the direct
medical cost of ARI in the UK was estimated to be about £86 million per year and £137 per
case. The study shows the substantial costs of ARI in otherwise healthy people presenting to
Table 2. Secondary care resource use and direct medical costs of acute respiratory illness during influenza seasons from 2001 to 2009 in the CPRD/HES population
and extrapolated to the UK population.
All hospital admissions Hospital admission via A&E Hospital admission via GP
referral
Hospital admission via other
route†
CPRD/HES Extrapolated CPRD/HES Extrapolated CPRD/HES Extrapolated CPRD/HES Extrapolated
Had� 1 hospital
admission, n, (% of
total population)
1,601 (1.0%) 58,067 908 (0.6%) 32,932 532 (0.3%) 19,295 161 (0.1%) 5,839
Absolute number of
admissions




1.2 (0.46) – 1.1 (0.38) 1.2 (0.47) – 1.4 (0.65) –
Absolute length of stay,
days
20,119 729,696 12,173 441,502 6,052 219,500 1,894 68,693
Mean length of stay
(SD)
11.3 (15.3) – 12.5 (17.3) – 9.9 (12.9) – 9.0 (8.2) –
Absolute total cost £13,801,634 £500,571,386 £8,350,678 £302,870,693 £4,151,672 £150,576,968 £1,299,284 £47,123,724






































Standard deviation; CPRD/HES, Clinical Practice Research Datalink/ Hospital Event Statistics database; A&E, accident and emergency, GP, general practitioner. †Other
routes of admission: elective, via bed bureau, via consultant outpatient clinic, via maternity unit, transfer from another hospital, unknown.
https://doi.org/10.1371/journal.pone.0236472.t002
Table 3. Resource use and direct medical costs of acute respiratory illness in hospitalised patients by influenza season in the CPRD/HES population and extrapo-
lated to the UK population.
Number of hospitalised patients Average length of stay, days Rate per 100,000 population Total hospital cost Extrapolated cost
2001/02 152 11.1 9.1 £1,273,892 £46,202,812
2002/03 162 9.9 9.7 £1,227,172 £44,508,313
2003/04 208 11.0 12.5 £1,763,805 £63,971,466
2004/05 189 11.6 11.4 £1,747,165 £63,367,945
2005/06 230 11.4 13.8 £2,154,609 £78,145,507
2006/07 214 10.6 12.9 £1,845,067 £66,918,743
2007/08 185 11.6 11.1 £1,703,719 £61,792,208
2008/09 214 12.8 12.9 £2,365,742 £85,803,090
CPRD/HES, Clinical Practice Research Datalink/ Hospital Event Statistics database.
https://doi.org/10.1371/journal.pone.0236472.t003
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primary care, with the greatest direct medical cost component due to hospital admissions,
largely among patients at high-risk of severe influenza outcomes.
Of the 156,193 patients with an ARI GP episode, 82,204 (52.6%) patients received a mean of
2.5 prescriptions. The cost in primary care in the total population study ranged from £666,420
in 2007/08 to £904,644 in 2003/04. Antibiotics accounted for about 40% of prescribed medica-
tions, whereas antiviral use was relatively low. The most commonly prescribed antibiotic was
penicillin at an average cost of £3,015,314 per year, followed by macrolides at an average cost
of £1,244,624 per year, whereas the average cost of Tamiflu was £61,539 per year, and of
Relenza was £36,003 per year.
The pattern of antibiotic prescribing in our study was broadly consistent with previous
reports in the UK including a CPRD study from 1991 to 1996, which showed that 59.4% of
patients with influenza-related primary care episodes received medication on prescription, of
which 45% were for antibiotics.[19] In a qualitative study of antibiotic prescribing in primary
care for cough and suspected lower respiratory tract infection (LRTI) in 13 European countries
including the UK (Cardiff and Southampton networks), 53% of patients received an antibiotic,
although there were wide regional differences; amoxicillin was the most commonly prescribed
antibiotic, accounting for 29% of prescriptions, ranging from 3% in Tromso to 83% in South-
ampton.[20] In a further study of primary care physicians in nine European countries, the
clinical factors most often cited as guiding antibiotic prescribing were auscultation findings,
fever, discoloured sputum, and breathlessness.[21]
Despite the wide use of antibiotics, it is likely that the majority of patients who are pre-
scribed them for respiratory illness in primary care have viral illness. For example, in a study
Table 4. Total direct medical costs of acute respiratory illness during influenza seasons from 2001 to 2009 in the CPRD/HES population and extrapolated to the
UK.
Total cost (SD) Total cost per case (SD) Extrapolated (SD)
Total population £21,343,445 (£10,441,364) £136.65 (£66.85) £774,105,286 (£378,697,772)
<5 years £263,949 (£63,813) £92.78 (£22.43) £9,573,164 (£2,314,433)
5–18 years £985,948 (£447,395) £57.19 (£25.95) £35,759,342 (£16,226,566)
19–49 years £4,829,902 (£1,964,789) £61.21 (£24.90) £175,175,688 (£71,260,921)
50–64 years £3,902,205 (£1,947,666) £116.32 (£58.06) £141,529,051 (£70,639,887)
�65 years £11,299,991 (£5,542,153) £477.72 (£234.30) £409,839,310 (£201,008,315)
CPRD/HES, Clinical Practice Research Datalink/ Hospital Event Statistics database; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0236472.t004
Table 5. Secondary care resource use for acute respiratory illness in high-risk patients extrapolated to the UK population for influenza seasons from 2001 to 2009.
Patients with�1
admission to hospital










Total 26,295 1.2 (0.53) 32,098 12.8 (17.1) 383,835 49,182
Respiratory 9,684 1.3 (0.64) 12,803 10.8 (12.0) 132,454 16,972
CNS 1,414 1.3 (0.58) 1,886 19.2 (37.2) 31,336 4,015
Diabetes 8,197 1.2 (0.50) 9,684 13.2 (17.6) 119,869 15,359
CHD 11,824 1.2 (0.52) 14,326 15.4 (20.4) 202,671 25,969
Liver disease 290 1.4 (0.52) 399 12.1 (10.2) 5,186 665
Renal disease 3,192 1.4 (0.70) 4,389 15.1 (14.6) 58,792 7,533
Immunocompromised 544 1.3 (0.62) 725 10.1 (7.5) 6,420 823
CPRD/HES, Clinical Practice Research Datalink/ Hospital Event Statistics database; SD, standard deviation; CHD, chronic heart disease, CNS, Central nervous system.
https://doi.org/10.1371/journal.pone.0236472.t005
PLOS ONE Acute respiratory illness in the United Kingdom
PLOS ONE | https://doi.org/10.1371/journal.pone.0236472 August 6, 2020 9 / 15
of children aged<12 years over four winters in the UK, among about 400 cases of cough and
fever for which GPs considered prescribing an antibiotic, 77% had a laboratory-confirmed
viral infection.[22] Furthermore, in a secondary care study conducted over three winters at a
hospital in the UK, of 780 patients admitted for an acute respiratory illness, 76% received an
antibiotic, and although bacterial infection was frequently confirmed in patients with COPD
and pneumonia, 21% of antibiotic use was in patients with no detectable bacterial infection.
[23] Antibiotics prescribed in primary care may improve serious outcomes in high-risk
patients with LRTI, although antibiotics are more often reported to have no benefit on symp-
tom severity or time to recovery in adults presenting to primary care with acute respiratory ill-
nesses caused by viral infection.[24, 25]
Resource use among patients with a GP episode of ARI and linked HES data was substantial
even though hospitalised patients represented only 1.0% of the population. A total of 1,601
patients were hospitalised during the study period, the majority of which were admitted once
(87%); 10.6% were admitted twice, and two patients were admitted 5 times. The mean number
of unique admissions per patient was 1.2 to 1.4 depending upon risk status. The highest rate of
hospitalisation was in patients aged�65 years (3.7%) or<5 years (2.1%), whereas the rate of
hospital admissions in the other age groups was <1%. In the previous analysis of the popula-
tion stratified by influenza vaccination status, although the majority of GP episodes of ARI
were in unvaccinated patients, a higher proportion of the vaccinated group (2.3%) were hospi-
talised than the unvaccinated group (0.5%). Hospitalised patients tended to be older with clini-
cal risk factors associated with serious influenza outcomes, and as such, were likely to have
been eligible for publically-funded vaccination.[4] In the total population, among high-risk
patients, we observed the highest hospital admission rates in those aged�65 years at a rate of
3,474 per 100,000 population.
The rates of hospitalisation observed in our study were substantially lower than those previ-
ously reported in England and Wales based on HES data,[26] which is expected given that our
study includes hospitalised patients who first presented to primary care, rather than all hospital
admissions in the HES. In a further study using data from in the UK from the Royal College of
General Practitioners’ database and the HES between 2000 and 2008, the highest rate of influ-
enza-related hospital admissions in patients without clinical risk factors was in infants aged
<6 months at 84.5 per 1000, followed by children aged 6 months to<4 years at 33.6 per 1000,
and adults aged�65 years at 12.1 per 1000.[12] The incidence of hospitalisation was relatively
low in healthy adults, and in all groups, the presence of clinical risk factors for influenza infec-
tion and related complications increased the risk of hospitalisation.[12]
Table 6. Total direct medical cost of acute respiratory illness in high-risk patients during influenza seasons from 2001 to 2009 in the CPRD/HES population and
extrapolated to the UK population.
CPRD/HES Extrapolated
Total cost (SD) Cost per case (SD) Total cost (SD) Cost per case (SD)
Respiratory £2,962,011 (£1,647,509) £441.89 (£245.79) £107,429,160 (£59,753,495) £16,027 (£8,915)
Central nervous system £722,220 (£604,167) £676.87 (£566.23) £26,194,193 (£21,912,530) £24,549 (£20,537)
Diabetes £2,821,988 (£1,549,777) £407.57 (£223.83) £102,350,667 (£56,208,853) £14,782 (£8,118)
Chronic heart disease £4,591,080 (£2,603,295) £516.96 (£293.13) £166,513,855 (£94,418,892) £18,750 (£10,632)
Liver disease £101,284 (£32,887) £565.83 (£183.72) £3,673,469 (£1,192,778) £20,522 (£6,663)
Renal disease £1,280,888 (£619,029) £13,772.99 (£6,656.23) £46,456,520 (£22,451,559) £499,532 (£241,415)
Immunocompromised £144,767 (£51,827) £689.37 (£246.80) £5,250,554 (£1,879,713) £25,003 (£8,951)
CPRD/HES, Clinical Practice Research Datalink/ Hospital Event Statistics database; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0236472.t006
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The vast majority of patients received only primary care at a cost of £6,506,137 over the
study period, whereas the cost of secondary care among the 1.0% of patients who were hospi-
talised was £13,801,634 over the study period. The mean cost of hospital admissions in the
total population was £9,302 per patient, in those admitted via A&E was £9,433 per patient, and
in those admitted by GP referral was £8,150 per patient. The mean cost per hospitalisation was
highest in patients with heart disease (£10,564), CNS disease (£13,171) and renal disease
(£10,359). In our previous analysis, in patients aged�65 years, influenza vaccination coverage
was high, peaking at 84.5% in 2005/06; despite this, the analysis of the total population showed
that the total direct medical cost of ARI was £477.72 per patient aged�65 years compared
with £61.21 per patient aged 19–49 years.
The cost-effectiveness of seasonal influenza vaccination campaigns is difficult to measure
because the clinical benefits of vaccination vary according to epidemic intensity, vaccine
match with circulating strains, and risk-factors of the population; moreover, measuring abso-
lute vaccine efficacy in elderly populations is not possible as the use of a placebo control is not
ethical. To guide public health decision-making, and to assess the real world burden of influ-
enza and the effectiveness of vaccination, many countries have established sentinel surveillance
networks. Recent sentinel swabbing surveillance schemes in seasons between 2010 and 2014 in
Europe and North America that assessed vaccine effectiveness for the prevention of labora-
tory-confirmed influenza, report adjusted effectiveness estimates from 23% to 75% in adults,
with most studies showing moderate effectiveness of about 45% to 55% in the general popula-
tion, and lower effectiveness in years of vaccine mismatch.[27–36] In a sentinel influenza sur-
veillance study in primary care in the UK, over three winters from 2004 to 2007, the yearly
adjusted vaccine effectiveness estimate was 55% to 67% in the general population, and 46% in
people aged�65 years.[37]
In most countries the aim of vaccinating elderly populations is to reduce hospitalisation
and death, but the wide-variation in vaccine effectiveness reported in this high-risk population
means that the benefit of vaccination against serious outcomes in elderly people remains a
matter for debate. Estimates of vaccine effectiveness in elderly populations hospitalised with
laboratory-confirmed influenza range from 33% to 86% in populations in Europe, North
America, and Australia.[27, 34, 37–49] Despite variations in the reported vaccine effectiveness,
cost-effectiveness models in various regions and settings generally show that vaccinating older
people is cost-effective, but given the clinical challenge of assessing serious outcomes in high-
risk patients, the benefits of vaccination are likely to have been underestimated. For example,
in Canada, a hospital-based sentential surveillance network was established in 2009 and has
since been prospectively monitoring seasonal influenza vaccine effectiveness in the prevention
of laboratory-confirmed influenza-hospitalisation over consecutive seasons. Based on influ-
enza-related hospitalisations in the 2011/2012 season, in people aged�65 years, the adjusted
vaccine effectiveness estimate was 58%, but after removing baseline frailty from the model, the
vaccine effectiveness was 43%.[50] This is the first sentinel study where vulnerability to illness
(frailty) was assessed in detail, and the effect of this risk-factor on serious influenza-outcomes
was substantial.[50]
Using READ codes to identify patients with clinical influenza syndromes including a range
of proxy diagnoses was the main limitation of our study. Although clinical diagnoses probably
vary in their sensitivity and specificity for ARI depending upon the patient age and co-morbid-
ities, logistic regression analysis of CPRD/HES data and weekly influenza activity from sentinel
surveillance showed a strong correlation between circulating influenza viruses and clinical epi-
sodes in the study (GP episodes of ARI, hospitalisations, and deaths).[13] However, the
resource use and costs are based on all ARI episodes and not the influenza-attributable rate.
Medications prescribed in hospital were not captured, as these are not collected as part of the
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HES data collection. The incidence of GP referrals to ambulatory out-patient appointments
was also not assessed, due to the scantiness of the data collection around this data point. A
strength of the study was the ability to follow patient journeys from the index episode in pri-
mary care, through to hospital admission and discharge, yet a limitation of this approach was
that the study did not identify all influenza-related hospital admissions, such as those admitted
via A&E without a previous GP visit. A further strength was that the study period of 2001 to
2009 was selected to provide estimates over multiple consecutive seasons, but not including
contemporary seasons during which episodes of ARI were unusually high due to, for example,
the circulation of A(H1N1)pdm09 (2009/10 season) and the emergence of an A(H3N2) strain
that was drifted from the vaccine strain (2014/15 season).[49]
In summary, this retrospective, cross-sectional study using the CPRD and linked HES data-
bases in the UK showed that the cost of ARI in primary care was £462,827 per 100,000 popula-
tion per year and the cost of linked hospital admissions was £981,808 per 100,000 population
per year. Extrapolating to the UK population, for 9 influenza seasons from 2001 to 2009, the
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